AC Immune SA (ACIU) said Tuesday that it will receive a second milestone payment of 24.6 million Swiss francs ($29.1 million) under its agreement with Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceuticals.
The milestone payment follows the rapid rate of prescreening in a trial of JNJ-2056 to treat preclinical Alzheimer's disease, AC Immune said.
Shares of AC Immune were up about 8% in Tuesday's premarket activity.
Price: 3.5300, Change: +0.26, Percent Change: +7.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.